US Court of Appeal affirmed PTAB and ITC decision favoring Jubilant Pharma, challenging Bracco's patent infringement claims

US Court of Appeal affirmed PTAB and ITC decision favoring Jubilant Pharma, challenging Bracco's patent infringement claims

The United States Court of Appeal affirmed the PTAB and US International Trade Commission decision favoring Jubilant Pharma Limited challenging Bracco's patent infringement claims.

Jubilant Pharma, a subsidiary of Jubilant Pharmova Limited announced its success at the Court of Appeals affirming the ruling from the PTAB and ITC. Bracco's patent infringement claims were successfully challenged in an Inter parties Review by Jubilant. The Inter Parties Review proceedings were held before the US Patent Office and International Trade Commission, wherein both the instance, Jubilant was successful.

Despite this, Bracco filed an appeal to the US Court of Appeal which was dismissed.

"The rulings demonstrate the uniqueness of our RUBY-FILL Generator and Elution system and its intellectual property and the strength of our research and development efforts" commented Sergio Calvo, President of Jubilant's Radiopharmaceuticals Division.

"The favorable ruling by the United States Court of Appeals further confirms Jubilant's right to continue development and commercialization of RUBY-FILL® in the U.S. marketplace and to continue focusing on our goal of bringing innovative products to the market for patients in need of the latest technology," stated Pramod Yadav, CEO, Jubilant Pharma Limited.